The Patent, Entitled "Cosmetic and Pharmaceutical Foam," Covers Foamix's
Emulsion-Based Foams and Their Use for Bacterial, Fungal and Viral Infections,
Inflammatory Conditions, and Many Other Disorders
REHOVOT, Israel, November 4 /PRNewswire/ -- Foamix Ltd., a leading
developer of topical foams for dermatological and gynecological use,
announced today that it has been awarded Mexican Patent Registration No.
268451 entitled "Cosmetic and Pharmaceutical Foam." The patent covers
Foamix's vehicles, compositions and cosmetic and pharmaceutical uses thereof
based on the company's Emollient Foam technology platform. Claimed uses
include the treatment of bacterial, fungal and viral infections, inflammatory
conditions, and many other dermatological and mucosal disorders, including
vaginal disorders.
"The continuing demand for our platform foam technology and our products
is international. By incorporating drugs in foam vehicles, we can achieve
advanced foam products with properties that afford higher patient compliance,
improved convenience, and better efficacy. Additionally, formulating active
ingredients in Foamix foam vehicles facilitates effective product life-cycle
management, backed by Foamix's extensive patent portfolio," said Dr. Dov
Tamarkin, the Company's CEO.
"We actively file for patent protection for our platform technologies and
range of products in development. A key component of our business strategy is
to create and build on a strong patent portfolio to offer protection to a
growing range of foam technologies and products, which we can license out to
our clients. Having an Emollient-Foam patent approved in Mexico is one more
degree of protection that we can provide to our licensees and add to our
granted "Cosmetic and Pharmaceutical Foam" patents in New Zealand and South
Africa," explained David Schuz, Foamix's Senior Vice President of
Intellectual Property and Head of Strategic Research.
Foamix expends significant resources on protecting its intellectual
property. To date, Foamix has seventeen issued patents worldwide covering its
foam and OilGel technology platforms and in excess of 150 pending
applications of which more than a third are filed in the United States. The
Company employs a leading U.S. patent counsel (WilmerHale LLC).
About Foamix
Headquartered in Rehovot, Israel, Foamix Ltd. is a leading developer of
topical and mucosal foams for dermatological and gynecological applications.
Foamix's state-of-the-art foams provide controlled delivery of a variety of
active ingredients. Foamix is currently collaborating with pharmaceutical and
cosmetic companies on a plurality of projects in the development of
proprietary dermatological and gynecologic foam drugs. Additionally, the
Company has an in-house pipeline of dermatological and gynecological drugs in
foam presentation. Foamix's psoriasis foam product licensed to Dr. Reddy's
Laboratories, Inc and marketed by Promius Pharma under the trade mark
Scytera(TM) has been launched in the United States in early 2009.
For additional information please visit http://www.foamix.co.il
Press inquiries: Sigal Maymon, Foamix Ltd, +972-8-9316233 or
info@foamix.co.il
SOURCE Foamix Ltd
Press inquiries: Sigal Maymon, Foamix Ltd, +972-8-9316233 or
info@foamix.co.il
